248 related articles for article (PubMed ID: 9442546)
1. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
[TBL] [Abstract][Full Text] [Related]
2. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome.
Sallee FR; Richman H; Beach K; Sethuraman G; Nesbitt L
J Am Acad Child Adolesc Psychiatry; 1996 Dec; 35(12):1647-56. PubMed ID: 8973072
[TBL] [Abstract][Full Text] [Related]
3. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder.
Delorme R; Chabane N; Callebert J; Falissard B; Mouren-Siméoni MC; Rouillon F; Launay JM; Leboyer M
J Clin Psychopharmacol; 2004 Feb; 24(1):18-23. PubMed ID: 14709942
[TBL] [Abstract][Full Text] [Related]
4. Platelet 3H-imipramine binding sites in obsessive-compulsive behavior.
Kim SW; Dysken MW; Pandey GN; Davis JM
Biol Psychiatry; 1991 Sep; 30(5):467-74. PubMed ID: 1657222
[TBL] [Abstract][Full Text] [Related]
5. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Mundo E; Maina G; Uslenghi C
Int Clin Psychopharmacol; 2000 Mar; 15(2):69-76. PubMed ID: 10759337
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
7. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
8. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Todorov C; Freeston MH; Borgeat F
Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
[TBL] [Abstract][Full Text] [Related]
9. Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients.
Marazziti D; Rossi A; Gemignani A; Giannaccini G; Pfanner C; Milanfranchi A; Presta S; Lucacchini A; Cassano GB
Neuropsychobiology; 1996; 34(4):184-7. PubMed ID: 9121618
[TBL] [Abstract][Full Text] [Related]
10. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
12. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
[TBL] [Abstract][Full Text] [Related]
13. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
Dell'Osso B; Allen A; Hollander E
Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
16. Tritiated imipramine binding in obsessive-compulsive volunteers and psychiatrically normal controls.
Black DW; Kelly M; Myers C; Noyes R
Biol Psychiatry; 1990 Feb; 27(3):319-27. PubMed ID: 2154266
[TBL] [Abstract][Full Text] [Related]
17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
18. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
Monteleone P; Catapano F; Di Martino S; Ferraro C; Maj M
Br J Psychiatry; 1997 Jun; 170():554-7. PubMed ID: 9330023
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
20. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
